OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of adjuvant chemoradiotherapy (CRT) versus chemotherapy (CT) for patients with gastric cancer. METHODS: Electronic databases including PUBMED, EMBASE, and Cochrane Library were retrieved for original studies from their inception to April 2014. Two reviewers independently evaluated the quality of the included studies and extracted the data. All Statistical analyses were performed using RevMan Version 5.2 software. RESULTS: Six randomized controlled trials involving 1,171 patients were included. The meta-analysis showed that there were statistical significances between chemoradiotherapy group and chemotherapy group in 5-year disease free survival rate (OR = 1.56, 95% CI: 1.09-2.24), local-regional recurrence rate (OR = 0.46, 95% CI: 0.32-0.67) and neutropenia (OR = 1.47, 95% CI: 1.11-1.96). While treatment efficacy did not differ significantly by the 5-year overall survival rate (OR = 1.32, 95% CI: 0.92-1.88), 3-year disease free survival rate (OR = 1.28, 95% CI: 0.92-1.80), and new metastases (OR = 0.76, 95% CI: 0.57-1.03). Toxicities were not significantly different between two groups for nausea/vomiting, diarrhea, anemia, and thrombocytopenia. CONCLUSIONS: For patients with gastric cancer, adjuvant chemoradiotherapy could significantly improve 5-year disease free survival rate and reduce local-regional recurrence rate compared with chemotherapy and, can be well accepted and tolerated.
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of adjuvant chemoradiotherapy (CRT) versus chemotherapy (CT) for patients with gastric cancer. METHODS: Electronic databases including PUBMED, EMBASE, and Cochrane Library were retrieved for original studies from their inception to April 2014. Two reviewers independently evaluated the quality of the included studies and extracted the data. All Statistical analyses were performed using RevMan Version 5.2 software. RESULTS: Six randomized controlled trials involving 1,171 patients were included. The meta-analysis showed that there were statistical significances between chemoradiotherapy group and chemotherapy group in 5-year disease free survival rate (OR = 1.56, 95% CI: 1.09-2.24), local-regional recurrence rate (OR = 0.46, 95% CI: 0.32-0.67) and neutropenia (OR = 1.47, 95% CI: 1.11-1.96). While treatment efficacy did not differ significantly by the 5-year overall survival rate (OR = 1.32, 95% CI: 0.92-1.88), 3-year disease free survival rate (OR = 1.28, 95% CI: 0.92-1.80), and new metastases (OR = 0.76, 95% CI: 0.57-1.03). Toxicities were not significantly different between two groups for nausea/vomiting, diarrhea, anemia, and thrombocytopenia. CONCLUSIONS: For patients with gastric cancer, adjuvant chemoradiotherapy could significantly improve 5-year disease free survival rate and reduce local-regional recurrence rate compared with chemotherapy and, can be well accepted and tolerated.
Authors: Kelly A Stahl; Elizabeth J Olecki; Matthew E Dixon; June S Peng; Madeline B Torres; Niraj J Gusani; Chan Shen Journal: Curr Oncol Date: 2020-12-24 Impact factor: 3.677
Authors: Joanna Gotfrit; Rachel Goodwin; Timothy Asmis; Angela J Hyde; Thierry Alcindor; Francine Aubin; Scott Berry; Dominick Bossé; Colin Brown; Ronald Burkes; Margot Burnell; Bruce Colwell; Jessica Corbett; Jeff Craswell; Nathalie Daaboul; Mark Doherty; D A Barry Fleming; Luisa Galvis; Rakesh Goel; Mohammed Harb; Alwin Jeyakumar; Derek Jonker; Erin Kennedy; Michael Lock; Aamer Mahmud; Patrick H McCrea; Vimoj Nair; Rami Nassabein; Carolyn Nessim; Ravi Ramjeesingh; Muhammad Raza; Wissam Saliba; Satareh Samimi; Simron Singh; Stephanie Snow; Mustapha Tehfé; Michael Thirlwell; Mario Valdes; Stephen Welch; Michael Vickers Journal: Curr Oncol Date: 2021-05-26 Impact factor: 3.677
Authors: Jeong Il Yu; Do Hoon Lim; Jeeyun Lee; Won Ki Kang; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Seung Tae Kim; Su Jin Lee; Sung Kim; Tae Sung Sohn; Jun Ho Lee; Ji Yeong An; Min Gew Choi; Jae Moon Bae; Heejin Yoo; Kyunga Kim Journal: Cancer Res Treat Date: 2018-10-01 Impact factor: 4.679